Stewart Denise, Javadi Masoud, Chambers Mariah, Gunsolly Chad, Gorski Grzegorz, Borghaei Ruth C
Department of Biochemistry and Molecular Biology, Philadelphia College of Osteopathic Medicine, Philadelphia, PA, USA.
BMC Mol Biol. 2007 Feb 23;8:12. doi: 10.1186/1471-2199-8-12.
Interleukin 4 (IL-4) has been shown to suppress interleukin-1 (IL-1) induced expression of matrix metalloproteinase-3 (MMP-3) in human synovial and gingival fibroblasts, but the mechanism of suppression has not been determined. Activators of peroxisome proliferator-activated receptor-gamma (PPARgamma) have been shown to inhibit cytokine induced expression of MMPs in other cell types, and IL-4 has been shown to activate PPARgamma by stimulating production of ligands through the lipoxygenase pathway. It has been suggested that PPARgamma may inhibit expression of MMPs by competing with transcription factor AP-1 for binding to a putative composite binding element in the promoters. The objective of this study was to determine whether the suppressive effects of IL-4 on the IL-1 induced expression of MMP-3 involve activation of lipoxygenase and/or PPARgamma.
Western blotting revealed the presence of PPARgamma in nuclear extract of HGF. IL-1 induced binding of nuclear extract to the putative composite PPRE/AP-1 site was diminished in the presence of pioglitazone, but there was no evidence of any change in the composition of the retarded complexes, and no evidence of PPARgamma binding to this site. Nordihydroguaiaretic acid (NDGA), a non-selective lipoxygenase inhibitor, and MK886, a specific inhibitor of 5-lipoxygenase, induced MMP-3 expression synergistically with IL-1. However IL-4 was still able to inhibit MMP-3 expression in the presence of NDGA or MK886 and IL-1. Activation of PPARgamma with pioglitazone not only failed to inhibit IL-1 induced expression of MMP-3 mRNA, but rather super-induced MMP-3 in the presence of IL-1. PPARgamma antagonist GW9662 failed to abolish the suppressive effects of IL-4. Another PPARgamma activator, 15-deoxy-Delta12,14prostaglandin J2 (15dPGJ2), also super-induced MMP-3 mRNA, and this was due at least in part to increased transcription.
IL-4 suppression of IL-1-induced MMP-3 expression in HGF is independent of lipoxygenase activity and activation of PPARgamma. Super-induction of MMP-3 by pioglitazone may have important implications for patients using pioglitazone to treat type II diabetes in the presence of chronic inflammation.
白细胞介素4(IL-4)已被证明可抑制白细胞介素-1(IL-1)诱导的人滑膜成纤维细胞和牙龈成纤维细胞中基质金属蛋白酶-3(MMP-3)的表达,但抑制机制尚未明确。过氧化物酶体增殖物激活受体γ(PPARγ)激活剂已被证明可抑制其他细胞类型中细胞因子诱导的基质金属蛋白酶表达,并且IL-4已被证明可通过脂氧合酶途径刺激配体产生来激活PPARγ。有人提出PPARγ可能通过与转录因子AP-1竞争结合启动子中的假定复合结合元件来抑制基质金属蛋白酶的表达。本研究的目的是确定IL-4对IL-1诱导的MMP-3表达的抑制作用是否涉及脂氧合酶和/或PPARγ的激活。
蛋白质印迹法显示人牙龈成纤维细胞(HGF)核提取物中存在PPARγ。在吡格列酮存在下,IL-1诱导的核提取物与假定的复合PPRE/AP-1位点的结合减少,但没有证据表明阻滞复合物的组成有任何变化,也没有证据表明PPARγ与该位点结合。去甲二氢愈创木酸(NDGA),一种非选择性脂氧合酶抑制剂,以及MK886,一种5-脂氧合酶的特异性抑制剂,与IL-1协同诱导MMP-3表达。然而,在NDGA或MK886和IL-1存在的情况下,IL-4仍然能够抑制MMP-3表达。用吡格列酮激活PPARγ不仅未能抑制IL-1诱导的MMP-3 mRNA表达,反而在IL-1存在的情况下超诱导MMP-3。PPARγ拮抗剂GW9662未能消除IL-4的抑制作用。另一种PPARγ激活剂,15-脱氧-Δ12,14-前列腺素J2(15dPGJ2),也超诱导MMP-3 mRNA,这至少部分是由于转录增加。
IL-4对HGF中IL-1诱导的MMP-3表达的抑制作用独立于脂氧合酶活性和PPARγ的激活。吡格列酮对MMP-3的超诱导可能对使用吡格列酮治疗存在慢性炎症的II型糖尿病患者具有重要意义。